83520-73-4

Upstream product

• 14741-71-0 ethyl (1H-benzimidazol-2-yl)acetate 
• 529-23-7 o-aminobenzaldehyde 
• 73568-25-9 2-chloro-3-quinoline carboxaldehyde 
• 95-54-5 1,2-diamino-benzene 
• 51-17-2 benzoimidazole 
• 939-16-2 3-bromoquinolin-2-one 
• 91301-03-0 3-formyl-2-quinolone 
• 103-84-4 Acetanilid 

Relevant academic research and scientific papers

A general Pd/Cu-catalyzed C-H heteroarylation of 3-bromoquinolin-2(1H)-ones

3-(Heteroaryl)quinolin-2(1H)-ones were synthesized in good to excellent yields using a bimetallic catalytic system through the C-H heteroarylation strategy. Starting from 3-bromoquinolin-2(1H)-ones, various azoles have been successfully used. In all cases, the reactions take place rapidly in dioxane and efficiently proceed in the presence of a bimetallic Pd(OAc)2/CuI as the catalyst, PPh3 as the ligand and LiOtBu or KOAc as the base. This journal is

FLUORESCENT DYE AGENT AND CARBOSTYRIL COMPOUND

PROBLEM TO BE SOLVED: To provide a novel fluorescent dye agent. SOLUTION: A fluorescent dye agent contains a carbostyril compound represented by formula (1) [in the formula (1), R1 is H, a halogen atom, a hydroxyl group, a cyano group, a nitro group or the like; R2 is O; R3 is a halogen atom, a carboxyl group, an ester group, an amide group or the like; R4-R6 and R8 independently represent H, a halogen atom, a nitro group, a cyano group or the like, where mutually adjacent groups of R4-R8 may be bound to form a ring; R7 is H, a substituted or unsubstituted aliphatic group or the like]. SELECTED DRAWING: None COPYRIGHT: (C)2019,JPOandINPIT

Design, synthesis and pharmacological evaluation of new 3-(1H-benzimidazol-2-yl)quinolin-2(1H)-one derivatives as potential antitumor agents

A series of new 3-(1H-benzimidazol-2-yl)quinolin-2(1H)-one derivatives (5a1?5d6) were designed and synthesized as antitumor agents. In vitro antitumor assay results showed that some compounds exhibited moderate to high inhibitory activity against HepG2, SK-OV-3, NCI-H460 and BEL-7404 tumor cell lines, and most compounds exhibited much lower cytotoxicity against the HL-7702 normal cell line compared to 5-FU and cisplatin. In vivo antitumor assay results demonstrated that 5a3 exhibited effective inhibition on tumor growth in the NCI-H460 xenograft mouse model and that 5d3 displayed excellent antiproliferative activity in the BEL-7402 xenograft model. These results suggested that both 5a3 and 5d3 could be used as anticancer drug candidates. Mechanistic studies suggested that compounds 5a3 and 5d3 exerted their antitumor activity by up-regulation of Bax, intracellular Ca2+ release, ROS generation, downregulation of Bcl-2, activation of caspase-9 and caspase-3 and subsequent cleavage of PARP, inhibition of CDK activity and activation of the p53 protein.

3-benzimidazole-2(1H)-quinolinone-ytterbium complex as well as preparation method and application thereof

The invention discloses a 3-benzimidazole-2(1H)-quinolinone-ytterbium complex as well as a preparation method and application thereof. The preparation method of the complex mainly comprises the following steps: taking a compound shown as a formula (II) and ytterbium nitrate hexahydrate or ytterbium nitrate pentahydrate, putting the substances into an organic solvent, and carrying out coordinationreaction under the condition of heating or not heating, thus obtaining a finished product. The inhibitory activity of the complex to certain cell lines is equivalent to that of a common antitumor drugcis-platinum; meanwhile, the toxicity of the complex to normal cells is significantly lower than that of the cis-platinum, so that the complex is expected to be used for preparing an anti-tumor drug.The structure of the complex disclosed by the invention is shown as the following formula (I); the structure of the compound shown as the raw material formula (II) involved in preparation of the complex is shown in the description.

A simple one-pot synthesis of new imidazol-2-yl-lh-quinolin-2-ones from the direct reaction of 2-chloroquinolin-3-carbaldehyde with aromatic o-diamines

An alternative and general one-pot synthesis of a library of novel imidazol-2-yl-1H-quinolin-2-one derivatives was performed in 70 % aqueous acetic acid by the direct reaction of 2-chloroquinolin-3-carbaldehyde with aromatic o-diamines. Experiments showed that adding Amberlyst (20% w/w) to the reaction media increased both the speed of reaction as well as the yield of products. Both DFT theoretical calculations and X-ray diffraction studies confirmed the proposed structures and the more stable conformation of the obtained products, Antitumor studies against sixty different cancer cell lines showed the potential of these kinds of compounds.

Design, structure-activity relationships and in vivo characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: Novel class of receptor tyrosine kinase inhibitors

The inhibition of key receptor tyrosine kinases (RTKs) that are implicated in tumor vasculature formation and maintenance, as well as tumor progression and metastasis, has been a major focus in oncology research over the last several years. Many potent small molecule inhibitors of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) kinases have been evaluated. More recently, compounds that act through the complex inhibition of multiple kinase targets have been reported and may exhibit improved clinical efficacy. We report herein a series of potent, orally efficacious 4-amino- 3-benzimidazol-2-ylhydroquinolin-2-one analogues as inhibitors of VEGF, PDGF, and fibroblast growth factor (FGF) receptor tyrosine kinases. Compounds in this class, such as 5 (TKI258), are reversible ATP- competitive inhibitors of VEGFR-2, FGFR-1, and PDGFRβ with IC50 values 0.1 μM. On the basis of its favorable in vitro and in vivo properties, compound 5 was selected for clinical evaluation and is currently in phase I clinical trials.

Tyrosine kinase inhibitors

The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such